目的： 探讨痰热清注射液治疗慢性阻塞性肺疾病急性加重 ((Acute exacerbation of chronic obstructive pulmonary disease, ,AECOPD))疗效,同时基于网络药理学及细胞实验验证其作用机制。方法： 选择80例AECOPD患者,随机分为对照组和联合组各40例；两组均给予西医常规治疗,联合组加用痰热清注射液治疗；比较两组中医临床疗效、炎性因子和安全性。利用TCMSP等数据库和Cytoscape 3.7.0 等软件筛选出痰热清注射液治疗AECOPD的作用机制,并通过人支气管上皮细胞16HBE实验验证。结果：① ①联合组中医临床有效率显著高于对照组(P < 0.05)；两组WBC、hs-CRP、IL-6和SAA较治疗前均显著下降(P < 0.05),且联合组显著低于对照组(P < 0.05)；两组不良反应比较无显著差异(P > 0.05)。②②网络药理学筛选得到IL-6、MAPK1、AKT1等关键靶点, IL-17 信号通路和PI3K-Akt 信号通路等关键通路。③③与空白组比较,模型组细胞中IL-6、p-AKT/AKT、PI3K蛋白表达均显著增高(P＜ < 0.01)；与模型组比较,痰热清注射液低、中、高剂量组IL-6、p-AKT、AKT、PI3K蛋白表达显著降低(P＜ < 0.05),且呈剂量依赖性。结论： 痰热清注射液可降低AECOPD患者炎症水平,提高中医临床疗效,其机制可能与抑制IL-6、p-AKT/AKT、PI3K等蛋白表达,调控PI3K-Akt信号通路相关。

: Objective: To explore the clinical efficacy of Tanreqing injection on patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and to explore its mechanism through network pharmacology and cell experiments. Methods: The 80 patients with AECOPD were divided into a control group and a combination group of 40 cases according to the random number method. Both groups were given conventional Western medicine treatment, and the combined group was treated with Tanreqing injection. The clinical efficacy of TCM, inflammatory factors and safety were compared between the two groups of patients. Databases such as TCMSP and software such as Cytoscape 3.7.0 were used to screen out the mechanism of Tanreqing injection in the treatment of AECOPD, and human bronchial epithelial cells (16HBE) were used for experimental verification. Results: ①①The clinical effective of TCM in the combined group was significantly higher than that in the control group (P < 0.05). WBC, hs-CRP, IL-6 and SAA in the two groups were significantly lower than before treatment (P < 0.05), and those of the combined group were significantly lower than those of Control group (P < 0.05). There was no statistically significant difference in adverse reactions between the two groups (P > 0.05). ②② such as quercetin, luteolin, and baicalein, key targets such as MAPK1, IL-6, AKT1, and key pathways such as IL-17 signaling pathway and PI3K-Akt signaling pathway were obtained by network pharmacology methods. ③Compared with the blank group, the expressions of IL-6, p-AKT/AKT and PI3K protein in the model group were significantly increased (P＜ < 0.01); Compared with the model group, the expression of IL-6, pAKT/AKT and PI3K protein in the Tanreqing extract group was significantly and dose-dependently reduced (P< < 0.05). Conclusion: Tanreqing injection can reduce the inflammation level and improve the clinical efficacy in AECOPD patients. Its mechanism may be related to the inhibition of protein expression including IL-6, p-AKT/AKT, and PI3K, and the regulation of the PI3K-Akt signaling pathway.

R285.6

2019 年度江苏省卫生健康委科技项目（H2019040）